Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Leukemia

  Free Subscription


Articles published in Cancer Chemother Pharmacol

Retrieve available abstracts of 38 articles:
HTML format



Single Articles


    January 2025
  1. MAHER KR, Shafer D, Schaar D, Bandyopadhyay D, et al
    A phase I study of MLN4924 and belinostat in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome.
    Cancer Chemother Pharmacol. 2025;95:24.
    PubMed     Abstract available


    December 2024
  2. MANGOURA SA, Abdel-Raheem MH, Eltyb HA, Molla MS, et al
    Influence of CYP2C8*3 and ABCG2 C421A genetic polymorphisms on trough concentration and molecular response of imatinib in Egyptian patients with chronic myeloid leukemia.
    Cancer Chemother Pharmacol. 2024;95:12.
    PubMed     Abstract available


  3. MATSUI M, Yasu T, Makimoto A, Yuza Y, et al
    Pharmacokinetic analysis of crushed venetoclax tablets combined with azacitizine for recurrent pediatric acute myeloid leukemia (AML).
    Cancer Chemother Pharmacol. 2024;95:1.
    PubMed     Abstract available


    September 2024
  4. CHRISTENSEN SR, Jensen CF, Heldrup J, Taylor Z, et al
    Hypoalbuminemia in children with acute lymphoblastic leukemia: relation to asparaginase therapy and impact on high dose methotrexate elimination.
    Cancer Chemother Pharmacol. 2024 Sep 21. doi: 10.1007/s00280-024-04713.
    PubMed     Abstract available


    July 2024
  5. RAHMAYANTI SU, Amalia R, Rusdiana T
    Systematic review: genetic polymorphisms in the pharmacokinetics of high-dose methotrexate in pediatric acute lymphoblastic leukemia patients.
    Cancer Chemother Pharmacol. 2024 Jul 13. doi: 10.1007/s00280-024-04694.
    PubMed     Abstract available


    June 2024
  6. CEREJA-PANTOJA KBC, de Brito Azevedo TC, Vinagre LWMS, de Moraes FCA, et al
    Alterations in pharmacogenetic genes and their implications for imatinib resistance in Chronic Myeloid Leukemia patients from an admixed population.
    Cancer Chemother Pharmacol. 2024 Jun 18. doi: 10.1007/s00280-024-04689.
    PubMed     Abstract available


  7. GAIETTO A, Panetta JC, Pauley JL, Relling MV, et al
    Ommaya reservoir use in pediatric ALL and NHL: a review at St. Jude Children's Research Hospital.
    Cancer Chemother Pharmacol. 2024;93:617-625.
    PubMed     Abstract available


    May 2024
  8. KOBAYASHI T, Sato H, Miura M, Fukushi Y, et al
    Overexposure to venetoclax is associated with prolonged-duration of neutropenia during venetoclax and azacitidine therapy in Japanese patients with acute myeloid leukemia.
    Cancer Chemother Pharmacol. 2024 May 23. doi: 10.1007/s00280-024-04673.
    PubMed     Abstract available


    March 2024
  9. DILLI BATCHA JS, Gota V, Matcha S, Raju AP, et al
    Predictive performance of population pharmacokinetic models of imatinib in chronic myeloid leukemia patients.
    Cancer Chemother Pharmacol. 2024 Mar 5. doi: 10.1007/s00280-024-04644.
    PubMed     Abstract available


  10. QU W, Lu J, Ji Y, He Z, et al
    Successful use of Palbociclib combined with Venetoclax and Azacitidine in an adult with refractory/relapsed therapy-related acute myeloid leukemia.
    Cancer Chemother Pharmacol. 2024 Mar 2. doi: 10.1007/s00280-024-04642.
    PubMed     Abstract available


    February 2024
  11. MARCELLETTI JF, Sikic BI
    Continuous 72-h infusion of zosuquidar with chemotherapy in patients with newly diagnosed acute myeloid leukemia stratified for leukemic blast P-glycoprotein phenotype.
    Cancer Chemother Pharmacol. 2024 Feb 26. doi: 10.1007/s00280-024-04656.
    PubMed     Abstract available


    October 2023
  12. BARNETT S, Nyein AC, Galler M, Jamieson D, et al
    Excessive vincristine exposure in a child being treated for acute lymphoblastic leukaemia with underlying Dubin-Johnson syndrome: a case report.
    Cancer Chemother Pharmacol. 2023;92:325-328.
    PubMed     Abstract available


    August 2023
  13. HE S, Shao Q, Zhao J, Bian J, et al
    Population pharmacokinetics and pharmacogenetics analyses of imatinib in Chinese patients with chronic myeloid leukemia in a real-world situation.
    Cancer Chemother Pharmacol. 2023 Aug 25. doi: 10.1007/s00280-023-04581.
    PubMed     Abstract available


  14. MARCELLETTI JF, Sikic BI
    A clinical trial of zosuquidar plus gemtuzumab ozogamicin (GO) in relapsed or refractory acute myeloid leukemia (RR AML): evidence of efficacy based on leukemic blast P-glycoprotein functional phenotype.
    Cancer Chemother Pharmacol. 2023 Aug 21. doi: 10.1007/s00280-023-04578.
    PubMed     Abstract available


    July 2023
  15. KAGAN AB, Moses BS, Lapidus R, Mott BT, et al
    ART714 is a best-in-class antileukemic 2-carbon-linked dimeric artemisinin derivative.
    Cancer Chemother Pharmacol. 2023;92:39-50.
    PubMed     Abstract available


    May 2023
  16. SINGH M, Bhaskar D, Bhatia P, Thakur R, et al
    Evaluation of FTO polymorphism in 6-mercaptopurine related intolerance in children with acute lymphoblastic leukemia.
    Cancer Chemother Pharmacol. 2023 May 31. doi: 10.1007/s00280-023-04546.
    PubMed     Abstract available


    April 2023
  17. KHERA S, Mahajan D, Barbind K, Dhingra S, et al
    Impact of pre-hydration duration on high-dose methotrexate induced nephrotoxicity in childhood acute lymphoblastic leukaemia in resource constraint centers: a randomized crossover study.
    Cancer Chemother Pharmacol. 2023;91:331-336.
    PubMed     Abstract available


    March 2023
  18. MONTESINOS P, Kota V, Brandwein J, Bousset P, et al
    A phase IV study evaluating QT interval, pharmacokinetics, and safety following fractionated dosing of gemtuzumab ozogamicin in patients with relapsed/refractory CD33-positive acute myeloid leukemia.
    Cancer Chemother Pharmacol. 2023 Mar 9:1-6. doi: 10.1007/s00280-023-04516.
    PubMed     Abstract available


  19. SHAFER D, Kagan AB, Rudek MA, Kmieciak M, et al
    Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies.
    Cancer Chemother Pharmacol. 2023;91:281-290.
    PubMed     Abstract available


  20. DONNETTE M, Osanno L, Giocanti M, Venton G, et al
    Determination of 5-azacitidine in human plasma by LC-MS/MS: application to pharmacokinetics pilot study in MDS/AML patients.
    Cancer Chemother Pharmacol. 2023;91:231-238.
    PubMed     Abstract available


    December 2022
  21. LI M, Kong XY, Wang SM
    Effects of splicing-regulatory polymorphisms in ABCC2, ABCG2, and ABCB1 on methotrexate exposure in Chinese children with acute lymphoblastic leukemia.
    Cancer Chemother Pharmacol. 2022 Dec 4. doi: 10.1007/s00280-022-04498.
    PubMed     Abstract available


  22. JOHNSON S, Dhamne C, Sankaran H, Gandhi KA, et al
    A prospective, open-label, randomised, parallel design study of 4 generic formulations of intramuscular L-asparaginase in childhood precursor B-cell acute lymphoblastic leukaemia (ALL).
    Cancer Chemother Pharmacol. 2022;90:445-453.
    PubMed     Abstract available


    November 2022
  23. JAISWAL A, Jaiswal A, Williamson EA, Gelfond J, et al
    Resistance to the BCL-XL degrader DT2216 in T-cell acute lymphoblastic leukemia is rare and correlates with decreased BCL-XL proteolysis.
    Cancer Chemother Pharmacol. 2022 Nov 8. pii: 10.1007/s00280-022-04490.
    PubMed     Abstract available


    August 2022
  24. SATO H, Kobayashi T, Fujita N, Yamashita T, et al
    Safe administration and pharmacokinetic monitoring of crushed venetoclax tablets with posaconazole and clarithromycin via percutaneous endoscopic gastrostomy tube in a patient with acute myeloid leukemia.
    Cancer Chemother Pharmacol. 2022 Aug 13. pii: 10.1007/s00280-022-04460.
    PubMed     Abstract available


  25. ZHANG W, Liu J, Li Y, Guo F, et al
    A bavachinin analog, D36, induces cell death by targeting both autophagy and apoptosis pathway in acute myeloid leukemia cells.
    Cancer Chemother Pharmacol. 2022 Aug 12. pii: 10.1007/s00280-022-04462.
    PubMed     Abstract available


    June 2022
  26. LIAO LH, Chen YQ, Huang DP, Wang LN, et al
    The comparison of plasma arsenic concentration and urinary arsenic excretion during treatment with Realgar-Indigo naturalis formula and arsenic trioxide in children with acute promyelocytic leukemia.
    Cancer Chemother Pharmacol. 2022 Jun 27. pii: 10.1007/s00280-022-04449.
    PubMed     Abstract available


  27. SECHAUD R, Sinclair K, Grosch K, Ouatas T, et al
    Evaluation of drug-drug interactions between midostaurin and strong CYP3A4 inhibitors in patients with FLT-3-mutated acute myeloid leukemia (AML).
    Cancer Chemother Pharmacol. 2022 Jun 25. pii: 10.1007/s00280-022-04448.
    PubMed     Abstract available


    March 2022
  28. FUKUDA N, Akamine Y, Abumiya M, Takahashi S, et al
    Relationship between achievement of major molecular response or deep molecular response and nilotinib plasma concentration in patients with chronic myeloid leukemia receiving first-line nilotinib therapy.
    Cancer Chemother Pharmacol. 2022 Mar 22. pii: 10.1007/s00280-022-04419.
    PubMed     Abstract available


    February 2022
  29. RAMALINGAM R, Kaur H, Scott JX, Sneha LM, et al
    Evaluation of cytogenetic and molecular markers with MTX-mediated toxicity in pediatric acute lymphoblastic leukemia patients.
    Cancer Chemother Pharmacol. 2022 Feb 14. pii: 10.1007/s00280-022-04405.
    PubMed     Abstract available


    January 2022
  30. LIU J, Luo W, Chen Q, Chen X, et al
    Curcumin sensitizes response to cytarabine in acute myeloid leukemia by regulating intestinal microbiota.
    Cancer Chemother Pharmacol. 2022 Jan 23. pii: 10.1007/s00280-021-04385.
    PubMed     Abstract available


    November 2021
  31. YOSHIDA K, Fujita A, Narazaki H, Asano T, et al
    Drug resistance to nelarabine in leukemia cell lines might be caused by reduced expression of deoxycytidine kinase through epigenetic mechanisms.
    Cancer Chemother Pharmacol. 2021 Nov 26. pii: 10.1007/s00280-021-04373.
    PubMed     Abstract available


  32. TONG WH
    Comment on "Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase".
    Cancer Chemother Pharmacol. 2021;88:919-920.
    PubMed    


    October 2021
  33. PANETTA JC, Liu Y, Bottiglieri T, Arning E, et al
    Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase.
    Cancer Chemother Pharmacol. 2021;88:655-664.
    PubMed     Abstract available


    September 2021
  34. CONDORELLI A, Matteo C, Leotta S, Schinina G, et al
    Venetoclax penetrates in cerebrospinal fluid of an acute myeloid leukemia patient with leptomeningeal involvement.
    Cancer Chemother Pharmacol. 2021 Sep 29. pii: 10.1007/s00280-021-04356.
    PubMed     Abstract available


    July 2021
  35. GOTO H, Yoshino Y, Ito M, Nagai J, et al
    Correction to: Aurora B kinase as a therapeutic target in acute lymphoblastic leukemia.
    Cancer Chemother Pharmacol. 2021 Jul 18. pii: 10.1007/s00280-021-04321.
    PubMed    


    June 2021
  36. TOKSVANG LN, Andres-Jensen L, Rank CU, Niinimaki R, et al
    Maintenance therapy and risk of osteonecrosis in children and young adults with acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study.
    Cancer Chemother Pharmacol. 2021 Jun 18. pii: 10.1007/s00280-021-04316.
    PubMed     Abstract available


    May 2021
  37. YOUSSEF YH, Makkeyah SM, Soliman AF, Meky NH, et al
    Influence of genetic variants in asparaginase pathway on the susceptibility to asparaginase-related toxicity and patients' outcome in childhood acute lymphoblastic leukemia.
    Cancer Chemother Pharmacol. 2021 May 7. pii: 10.1007/s00280-021-04290.
    PubMed     Abstract available


    April 2021
  38. NIELSEN SN, Toksvang LN, Grell K, Nersting J, et al
    No association between relapse hazard and thiopurine methyltransferase geno- or phenotypes in non-high risk acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study.
    Cancer Chemother Pharmacol. 2021 Apr 29. pii: 10.1007/s00280-021-04281.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.